Description
Mirodenafil research compound
Mirodenafil is a pyrrolopyrimidinone PDE5 inhibitor developed in South Korea.
Product details
| Compound | Mirodenafil |
|---|---|
| Class | PDE5 inhibitor |
| Form | Liquid; Tablets |
| Strength | 30ml/33mg per ml/1000mg; 50mg per tablet/20ct/1g; 50mg per tablet/40ct/2g |
| Labelling | Compound name and strength on every container |
Select your format and strength from the options above.
What research has examined
- PDE5 inhibition: enzyme selectivity research.
- cGMP signalling: smooth-muscle models.
- Neuroscience: preclinical cognition research.
Research interest does not establish a proven effect in humans.
Regulatory status
Mirodenafil is licensed in South Korea but not by the FDA or EMA. Supplied as a research chemical only.
Storage and handling
Keep the container tightly closed, at room temperature or cooler, away from moisture and light.
Related research products
Stenabolic (SR-9009) · Raloxifene Liquid · Letrozole · All research liquids
References
For laboratory research use only. Not for human or animal consumption. Not intended to diagnose, treat, cure or prevent any disease.
Reviews
There are no reviews yet.